



## The Medicines Patent Pool Foundation Chair's Summary

**29 April 2026 (via correspondence)**

The Governance Board of the Medicines Patent Pool (**MPP**) thanks the Expert Advisory Group (**EAG**) and members of the Scientific Advisory Panel and Community Advisory Panel for their report assessing the final results of negotiations between MPP and F. Hoffmann-La Roche Ltd. (**Roche**) on a licence agreement relating to baloxavir marboxil (**Agreement**).

The Board has reviewed the EAG report and the proposed Agreement between MPP and Roche.

The Board agrees with the EAG's assessment that the proposed collaboration is consistent with the MPP's mandate as defined in its Statutes and that the negotiation results offer sufficient added value over the status quo.

Therefore, the Board requests the Executive Director to finalise and sign the necessary documents with Roche to formalise the collaboration.